AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Acrivon Therapeutics, Inc. Common Stock
Video analysis: ACRV
All videosNo video analysis for this stock yet. Request one from our team.
News: ACRV
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
Acrivon Therapeutics, Inc. (ACRV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACRV's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D.
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations Dose expansion to evaluate biomarker-selected small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma (adNSCLC), as well as endometrial, cervical, and esophago-gastric junction cancers WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that ACR-2316 has advanced into the randomized dose expansion portion of its ongoing Phase 1/2 study.
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index
Acrivon Therapeutics: Priced For Failure, Built For Precision
Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching for kinase inhibitor therapies, showing a 50% response rate in serous endometrial cancer with ACR-368. Key near-term catalysts include Phase 2b ACR-368 data and Phase 1 ACR-2316 expansion results, both critical for de-risking and expanding commercial potential.
